Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$106.53 +2.0%	$102.22	$76.53 ▼ $131.49	$25.10B	1.29	950,678 shs	721,507 shs
JNJ Johnson & Johnson	$149.81 -0.6%	$154.07	$140.68 ▼ $169.99	$362.67B	0.42	8.02 million shs	22.59 million shs
MRNA Moderna	$25.90 +2.0%	$26.29	$23.15 ▼ $138.07	$9.82B	1.86	8.49 million shs	13.76 million shs
PFE Pfizer	$23.97 +0.4%	$23.26	$20.92 ▼ $31.54	$135.77B	0.57	41.38 million shs	62.63 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+2.04%	-0.04%	+7.51%	+11.69%	+23.48%
JNJ Johnson & Johnson	-0.64%	-4.52%	-2.19%	-8.32%	+2.85%
MRNA Moderna	+1.97%	-2.89%	+0.39%	-20.70%	-80.57%
PFE Pfizer	+0.39%	-2.22%	+3.94%	-8.53%	-12.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.6447 of 5 stars	4.4	3.0	0.0	0.0	1.6	0.8	0.0
JNJ Johnson & Johnson	4.9349 of 5 stars	3.3	5.0	4.2	3.9	3.0	1.7	1.9
MRNA Moderna	4.4697 of 5 stars	4.0	2.0	0.0	4.6	1.5	2.5	1.3
PFE Pfizer	4.8782 of 5 stars	2.3	4.0	4.2	4.3	2.9	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$137.86	29.41% Upside
JNJ Johnson & Johnson	2.55	Moderate Buy	$170.88	14.07% Upside
MRNA Moderna	2.04	Hold	$46.61	79.97% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	21.69% Upside

Current Analyst Ratings Breakdown

Latest BNTX, PFE, MRNA, and JNJ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/5/2025	JNJ Johnson & Johnson	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$181.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.60	N/A	N/A	$87.61 per share	1.22
JNJ Johnson & Johnson	$89.33B	4.03	$13.04 per share	11.49	$29.69 per share	5.05
MRNA Moderna	$3.24B	3.10	N/A	N/A	$28.33 per share	0.91
PFE Pfizer	$63.63B	2.14	$4.38 per share	5.47	$15.62 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$8.99	16.66	13.53	2.28	24.42%	33.46%	13.30%	7/16/2025 (Estimated)
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.37	7.91	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)

Latest BNTX, PFE, MRNA, and JNJ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/16/2025	Q2 2025	JNJ Johnson & Johnson	$2.65	N/A	N/A	N/A	$22.85 billion	N/A
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion
4/15/2025	Q1 2025	JNJ Johnson & Johnson	$2.59	$2.77	+$0.18	$4.54	$21.65 billion	$21.89 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
JNJ Johnson & Johnson	$5.20	3.47%	N/A	57.84%	64 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.18%	N/A	124.64%	16 Years

Latest BNTX, PFE, MRNA, and JNJ Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025
4/15/2025	JNJ Johnson & Johnson	quarterly	$1.30	3.37%	5/27/2025	5/27/2025	6/10/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
JNJ Johnson & Johnson	0.49	1.26	1.03
MRNA Moderna	N/A	4.22	4.14
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
JNJ Johnson & Johnson	138,100	2.41 billion	2.40 billion	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

BNTX, PFE, MRNA, and JNJ Headlines

Recent News About These Companies

Center For Asset Management LLC Reduces Stake in Pfizer Inc. (NYSE:PFE)

June 21 at 7:21 AM | marketbeat.com

Woodmont Investment Counsel LLC Acquires 16,987 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 7:00 AM | marketbeat.com

Monte Financial Group LLC Purchases 43,740 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 6:50 AM | marketbeat.com

World Equity Group Inc. Sells 38,707 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 6:25 AM | marketbeat.com

PFG Investments LLC Grows Position in Pfizer Inc. (NYSE:PFE)

June 21 at 5:50 AM | marketbeat.com

Advocate Group LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

June 21 at 5:50 AM | marketbeat.com

Advisor Resource Council Invests $1.55 Million in Pfizer Inc. (NYSE:PFE)

June 21 at 5:21 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Reduced by United Advisor Group LLC

June 21 at 4:39 AM | marketbeat.com

Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging

June 20 at 2:24 PM | finance.yahoo.com

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

June 20 at 11:06 AM | zacks.com

June 20 at 10:00 AM | zacks.com

Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out

June 20 at 9:06 AM | seekingalpha.com

Private Wealth Partners LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 7:36 AM | marketbeat.com

Cantor Fitzgerald Investment Advisors L.P. Sells 14,500 Shares of Pfizer Inc. (NYSE:PFE)

June 20 at 7:26 AM | marketbeat.com

Good Steward Wealth Advisors LLC Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 6:33 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Means Investment CO. Inc.

June 20 at 5:48 AM | marketbeat.com

Pfizer: An Offensive Play For A Bear Market

June 20 at 5:20 AM | seekingalpha.com

Envestnet Portfolio Solutions Inc. Trims Stake in Pfizer Inc. (NYSE:PFE)

June 20 at 5:03 AM | marketbeat.com

Pfizer: An Offensive Play For A Bear Market

June 20 at 5:01 AM | seekingalpha.com

Pfizer Inc. (NYSE:PFE) Shares Bought by Johnson Investment Counsel Inc.

June 20 at 4:42 AM | marketbeat.com

Wealth Enhancement Advisory Services LLC Has $66.04 Million Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 3:47 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
By Jeffrey Neal Johnson | May 23, 2025
View Pfizer's 7.5% Dividend: Income Haven or House of Cards?
3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market
By Chris Markoch | May 22, 2025
View 3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market

BNTX, PFE, MRNA, and JNJ Company Descriptions

BioNTech NASDAQ:BNTX

$106.53 +2.13 (+2.04%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$105.60 -0.93 (-0.87%)

As of 06/20/2025 07:22 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Johnson & Johnson NYSE:JNJ

$149.81 -0.92 (-0.61%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$149.78 -0.03 (-0.02%)

As of 06/20/2025 07:55 PM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$25.90 +0.50 (+1.97%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$25.93 +0.03 (+0.12%)

As of 06/20/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Pfizer NYSE:PFE

$23.97 +0.09 (+0.37%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$23.99 +0.02 (+0.09%)

As of 06/20/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time